RTW INVESTMENTS, LP
NEW YORK, NY · CIK 1493215 · 13F filing filed 2026-08-14
SEC-registered investment adviser since 2013 · limited partnership
- Assets managed$14.1bn
- Staff70 · 35 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds3 (2 hedge) · $13.1bn gross assets
- Websitertwfunds.com
- Form ADV · 2026-03-30SEC adviser record
- Legal entityRTW INVESTMENTS, LP (US)
$11.7bn
reported value
+16.5% vs Q1 2026
84positions
47.7%in top 10
9 new
26 added
8 reduced
13 sold out
vs Q1 2026
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MADRIGAL PHARMACEUTICALS INC MDGL | $1.1bn9.14% | Unchanged |
| ARGENX SE ARGX | $658.2m5.62% | Unchanged |
| PTC THERAPEUTICS INC PTCT | $631.9m5.39% | Unchanged |
| PROTAGONIST THERAPEUTICS INC PTGX | $620.4m5.30% | Added +2.1k |
| CG ONCOLOGY INC CGON | $605.0m5.16% | Added +1.5m |
| INSMED INC INSM | $516.3m4.41% | Unchanged |
| TANGO THERAPEUTICS INC TNGX | $434.5m3.71% | Added +600.0k |
| SPYRE THERAPEUTICS INC SYRE | $377.5m3.22% | Added +80.0k |
| CELCUITY INC CELC | $345.8m2.95% | Added +265.3k |
| ERASCA INC ERAS | $328.8m2.81% | Added +1.8m |
| RADNET INC RDNT | $298.9m2.55% | Added +562.0k |
| ORUKA THERAPEUTICS INC ORKA | $298.7m2.55% | Added +1.1m |
| NATERA INC NTRA | $271.4m2.32% | Reduced -250.0k |
| ULTRAGENYX PHARMACEUTICAL IN RARE | $260.3m2.22% | Added +4.1m |
| IRHYTHM TECHNOLOGIES INC IRTC | $259.6m2.22% | Added +514.1k |
| CYTOKINETICS INC CYTK | $243.8m2.08% | Added +140.8k |
| KAILERA THERAPEUTICS INC KLRA | $237.4m2.03% | New |
| ESTABLISHMENT LABS HLDGS INC ESTA | $227.9m1.95% | Unchanged |
| GUARDANT HEALTH INC GH | $222.2m1.90% | Unchanged |
| NEUROCRINE BIOSCIENCES INC NBIX | $213.7m1.82% | Added +205.9k |
| TARSUS PHARMACEUTICALS INC TARS | $211.3m1.80% | Added +11.0k |
| STOKE THERAPEUTICS INC STOK | $184.0m1.57% | Unchanged |
| UNIQURE NV QURE | $181.5m1.55% | Added +1.4m |
| ACADIA PHARMACEUTICALS INC ACAD | $180.8m1.54% | Unchanged |
| REPLIGEN CORP RGEN | $169.3m1.45% | Added +34.6k |
| UROGEN PHARMA LTD URGN | $167.2m1.43% | Unchanged |
| GH RESEARCH PLC GHRS | $159.5m1.36% | Unchanged |
| IMMUNOCORE HLDGS PLC IMCR | $154.6m1.32% | Unchanged |
| COMPASS PATHWAYS PLC CMPS | $151.4m1.29% | Added +68.6k |
| IMMATICS N.V IMTX | $131.1m1.12% | Added +76.8k |
| ZAI LAB LTD ZLAB | $124.9m1.07% | Unchanged |
| IMMUNOVANT INC IMVT | $122.4m1.05% | Unchanged |
| BELITE BIO INC BLTE | $110.2m0.94% | Unchanged |
| XENCOR INC XNCR | $109.1m0.93% | Unchanged |
| TAYSHA GENE THERAPIES INC TSHA | $92.3m0.79% | Reduced -120.0k |
| COGENT BIOSCIENCES INC COGT | $89.4m0.76% | Reduced -3.1m |
| ALKERMES PLC ALKS | $87.6m0.75% | Unchanged |
| STRUCTURE THERAPEUTICS INC GPCR | $86.3m0.74% | New |
| REPLIMUNE GROUP INC REPL | $82.0m0.70% | Added +54.7k |
| CASTLE BIOSCIENCES INC CSTL | $66.3m0.57% | Added +20.0k |
| CANDEL THERAPEUTICS INC CADL | $66.1m0.56% | Unchanged |
| ROCKET PHARMACEUTICALS INC RCKT | $60.5m0.52% | Unchanged |
| KODIAK SCIENCES INC KOD | $58.0m0.49% | Unchanged |
| AKTIS ONCOLOGY INC AKTS | $51.3m0.44% | Unchanged |
| AXOGEN INC AXGN | $46.7m0.40% | New |
| DANAHER CORPORATION DHR | $43.8m0.37% | New |
| CULLINAN THERAPEUTICS INC CGEM | $43.1m0.37% | Added +658.4k |
| NEUROGENE INC NGNE | $42.8m0.37% | Unchanged |
| HINGE HEALTH INC HNGE | $41.5m0.35% | Reduced -1.4m |
| ORCHESTRA BIOMED HLDGS INC OBIO | $41.2m0.35% | Added +1.2m |
| SOLID BIOSCIENCES INC SLDB | $38.9m0.33% | New |
| SAVARA INC SVRA | $36.7m0.31% | Unchanged |
| AQUESTIVE THERAPEUTICS INC AQST | $30.9m0.26% | Unchanged |
| KYMERA THERAPEUTICS INC KYMR | $27.5m0.23% | Unchanged |
| VERASTEM INC VSTM | $25.3m0.22% | Added +59.5k |
| DIANTHUS THERAPEUTICS INC DNTH | $24.2m0.21% | Unchanged |
| BETA BIONICS INC BBNX | $23.5m0.20% | Reduced -500.0k |
| CENTURY THERAPEUTICS INC IPSC | $21.3m0.18% | Unchanged |
| EVOMMUNE INC EVMN | $20.0m0.17% | Unchanged |
| BEAM THERAPEUTICS INC BEAM | $19.6m0.17% | Unchanged |
| DEFINIUM THERAPEUTICS INC DFTX | $18.8m0.16% | Added +100.0k |
| IDEAYA BIOSCIENCES INC IDYA | $13.8m0.12% | New |
| ATAIBECKLEY INC ATAI | $10.5m0.09% | Unchanged |
| MILESTONE PHARMACEUTICALS IN MIST | $10.5m0.09% | Added +1.5m |
| OCUGEN INC OCGN | $10.2m0.09% | Unchanged |
| TENAX THERAPEUTICS INC TENX | $10.1m0.09% | Added +326.3k |
| HEARTFLOW INC HTFL | $8.7m0.07% | Reduced -200.0k |
| PERCEPTIVE CAP SOLUTIONS COR FRNM | $8.1m0.07% | Unchanged |
| WAVE LIFE SCIENCES LTD 96663EUR | $7.8m0.07% | Unchanged |
| LARIMAR THERAPEUTICS INC LRMR | $7.8m0.07% | Added +1.1m |
| LUMEXA IMAGING HOLDINGS INC LMRI | $7.3m0.06% | Unchanged |
| ALLOGENE THERAPEUTICS INC ALLO | $6.8m0.06% | New |
| CRESCENT BIOPHARMA INC. CBIO | $6.7m0.06% | Unchanged |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $6.3m0.05% | Unchanged |
| MAZE THERAPEUTICS INC MAZE | $6.3m0.05% | New |
| CAPRICOR THERAPEUTICS INC CAPR | $6.0m0.05% | Unchanged |
| KALARIS THERAPEUTICS INC KLRS | $5.3m0.05% | Unchanged |
| ABIVAX SA ABVX | $3.5m0.03% | New |
| AVALO THERAPEUTICS INC AVTX | $3.2m0.03% | Reduced -682.0k |
| MEDLINE INC MDLN | $2.8m0.02% | Unchanged |
| DISC MEDICINE INC IRON | $2.2m0.02% | Unchanged |
| IMAGENEBIO INC IMA | $2.0m0.02% | Unchanged |
| EXAGEN INC XGN | $906.8k0.01% | Reduced -200.2k |
| ROCKET PHARMACEUTICALS INC *W EXP 09/02/202 | $1.2k0.00% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| APOGEE THERAPEUTICS INC | $234.2m2.8m shares |
| APELLIS PHARMACEUTICALS INC APLS | $148.2m3.7m shares |
| INTUITIVE SURGICAL INC ISRG | $101.4m220.0k shares |
| CENTESSA PHARMACEUTICALS PLC | $81.6m2.1m shares |
| CRINETICS PHARMACEUTICALS IN CRNX | $52.7m1.5m shares |
| WAYSTAR HLDG CORP WAY | $39.3m1.6m shares |
| ARROWHEAD PHARMACEUTICALS IN ARWR | $36.7m585.7k shares |
| STRYKER CORPORATION SYK | $32.9m100.0k shares |
| COMPASS THERAPEUTICS INC CMPX | $22.1m4.2m shares |
| FULGENT GENETICS INC FLGT | $20.5m1.3m shares |
| JADE BIOSCIENCES INC JBIO | $8.1m573.2k shares |
| INVENTIVA SA IVA | $7.2m1.3m shares |
| OMADA HEALTH INC OMDA | $2.5m200.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 34.
| Company | Stake |
|---|---|
| ALLURION TECHNOLOGIES INC 13D · filed 2026-03-02 | 39.4% |
| ORCHESTRA BIOMED HLDGS INC OBIO · 13D · filed 2026-04-29 | 19.2%≈ $51.5m |
| ALLURION TECHNOLOGIES INC 13D · filed 2025-02-24 | 17.6% |
| ESTABLISHMENT LABS HLDGS INC ESTA · 13G · filed 2025-02-14 | 10.0%≈ $242.2m |
| NEUROGENE INC NGNE · 13G · filed 2025-02-14 | 10.0%≈ $47.1m |
| TENAX THERAPEUTICS INC TENX · 13G · filed 2026-08-14 | 9.9%≈ $41.7m |
| MILESTONE PHARMACEUTICALS IN MIST · 13G · filed 2026-05-15 | 9.9%≈ $16.6m |
| STOKE THERAPEUTICS INC STOK · 13G · filed 2026-05-15 | 9.9%≈ $194.4m |
| COMPASS PATHWAYS PLC CMPS · 13G · filed 2026-05-15 | 9.9% |
| VERASTEM INC VSTM · 13G · filed 2026-05-15 | 9.9%≈ $34.5m |
| CG ONCOLOGY INC CGON · 13G · filed 2026-08-14 | 9.7%≈ $605.0m |
| IMMATICS N.V IMTX · 13G · filed 2026-05-15 | 9.6%≈ $130.4m |
| CASTLE BIOSCIENCES INC CSTL · 13G · filed 2026-05-15 | 9.3%≈ $65.8m |
| TANGO THERAPEUTICS INC TNGX · 13G · filed 2026-05-15 | 9.3%≈ $415.8m |
| REPLIMUNE GROUP INC REPL · 13G · filed 2026-05-15 | 8.9%≈ $81.4m |
| GH RESEARCH PLC GHRS · 13G · filed 2025-05-15 | 8.9%≈ $147.8m |
| RAPT THERAPEUTICS INC 13G · filed 2025-05-15 | 8.9% |
| CANDEL THERAPEUTICS INC CADL · 13G · filed 2026-05-15 | 8.8%≈ $66.1m |
| XENCOR INC XNCR · 13G · filed 2025-11-14 | 8.7%≈ $100.2m |
| KAILERA THERAPEUTICS INC KLRA · 13G · filed 2026-08-14 | 8.3%≈ $237.4m |
| PROTAGONIST THERAPEUTICS INC PTGX · 13G · filed 2026-02-17 | 8.1%≈ $620.1m |
| TARSUS PHARMACEUTICALS INC TARS · 13G · filed 2025-08-14 | 8.1%≈ $215.5m |
| ULTRAGENYX PHARMACEUTICAL IN RARE · 13G · filed 2026-08-14 | 7.9%≈ $260.3m |
| CENTURY THERAPEUTICS INC IPSC · 13G · filed 2026-05-15 | 7.1%≈ $32.0m |
| TAYSHA GENE THERAPIES INC TSHA · 13G · filed 2026-05-15 | 7.0%≈ $140.9m |
Trades reported as a company insider since 1 Apr 2026
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2026-04-27 | ORCHESTRA BIOMED HLDGS INC 10% owner · See footnote | Sold | $13232 shares |
| 2026-04-20 | KAILERA THERAPEUTICS INC 10% owner · See footnote | Bought | $8.0m500.0k shares |